EN DE

Grand Brilliance Group Holdings Ltd (8372) Fair Value & Analysis

Healthcare · HK · Market cap HK$112M

GB Grand Brilliance Group Holdings Ltd 8372 · HK
PriceHK$0.1440
Fair ValueHK$0.1500
Upside+4.2%
Quality60/100
Watch Grand Brilliance Group Holdings Ltd for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Thin margins · 8.4% net margin
generates free cash flow
2.27% dividend yield
Mixed vs. peers (7/13)
Narrow moat 35/100
Evidence: High Range HK$0.1100 – HK$0.2000 Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated 3 days ago

Share price +9.1% over the past month.

A solid business, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • A fairly wide model range (HK$0.1100 to HK$0.2000) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$0.1630 HK$0.0527 Fair Value HK$0.1500 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.0527 – HK$0.1630 · fair‑value band HK$0.1100 – HK$0.2000 · the HK$0.1440 price screens below the HK$0.1500 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Grand Brilliance Group Holdings Ltd (8372) currently trades at HK$0.1440, while our model-based Fair Value estimate is HK$0.1500, implying the stock looks roughly 4.2% fairly valued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Grand Brilliance Group Holdings Ltd generated revenue of HK$101M at a net margin of 8.4%. Revenue declined 8.6% year over year. It earns a return on equity of 7.1%. The balance sheet holds a net cash position of HK$51.1M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.1100 (bear case) to HK$0.2000 (bull case); at HK$0.1440, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 50% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -7% fair-value upside, at 4%, 8372 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income HK$0.1100 HK$0.1100 HK$0.1000 76
Growth DCF HK$0.0800 HK$0.0800 HK$0.0900 72
Gordon GGM HK$0.0200 HK$0.0300 HK$0.0400 70
All 26 models by family
DCF Models
FCF DCF HK$0.0800 HK$0.0800 HK$0.0900 38
Owner Earnings HK$0.1900 HK$0.2400 HK$0.3100 31
5Y Revenue Exit HK$0.1100 HK$0.1500 HK$0.2000 39
5Y EBITDA Exit HK$0.1400 HK$0.2000 HK$0.2800 41
5Y P/E Exit HK$0.1600 HK$0.2400 HK$0.3200 38
10Y Revenue Exit HK$0.1000 HK$0.1200 HK$0.1600 36
10Y EBITDA Exit HK$0.1100 HK$0.1500 HK$0.2100 37
10Y P/E Exit HK$0.1200 HK$0.1800 HK$0.2400 35
Earnings-Based
Graham-Dodd HK$0.0700 HK$0.2400 HK$0.3200 54
Lynch FV HK$0.0500 HK$0.0800 HK$0.1000 50
PEG = 1.0 HK$0.0500 HK$0.0800 HK$0.1000 46
EPV HK$0.1200 HK$0.1200 HK$0.1300 59
Dividend Discount
Gordon GGM HK$0.0200 HK$0.0300 HK$0.0400 70
DDM Multi-Stage HK$0.0200 HK$0.0300 HK$0.0300 61
Multiples
P/E Multiple HK$0.1700 HK$0.2300 HK$0.2900 63
P/S Multiple HK$0.1300 HK$0.1800 HK$0.2200 58
P/B Multiple HK$0.1300 HK$0.1800 HK$0.2200 55
EV/EBIT HK$0.1700 HK$0.2100 HK$0.2500 53
EV/EBITDA HK$0.2000 HK$0.2500 HK$0.2900 54
EV/Revenue HK$0.1400 HK$0.1800 HK$0.2100 43
Asset-Based
NCAV (Graham) HK$0.0700 HK$0.1000 HK$0.1500 50
Growth DCF
Growth DCF HK$0.0800 HK$0.0800 HK$0.0900 72
Rev-Margin DCF HK$0.1100 HK$0.1500 HK$0.1900 67
Economic Profit
Residual Income HK$0.1100 HK$0.1100 HK$0.1000 76
ROIC Compounder HK$0.1200 HK$0.1200 HK$0.1300 67
Growth Earnings
Growth-Adj P/E HK$0.1500 HK$0.2100 HK$0.2700 68

Widest divergence: Growth Earnings (HK$0.2100) versus Dividend Discount (HK$0.0300). Highest evidence: Residual Income (76).

Notify me when 8372 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$101M
Revenue growth (YoY) -8.6%
Net margin 8.4%
Return on equity 7.1%
Free cash flow HK$1.2M FY2025
P/E ratio 14.0 as of Jul 2, 2026
More key figures
Operating margin 7.8%
EPS (TTM) HK$0.0200
Dividend yield 2.3%
EPS growth (YoY) -27.5%
Net cash HK$51.1M FY2026

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 60/100

Of which business quality 61 · Market factors (momentum, volatility) 52

Profitability 47
Margins and returns on capital today
Quality Growth 29
Are margins and returns improving?
Cashflow 31
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 81
Disciplined investing over empire-building
Low Volatility 61
Calm price path (market factor)
Momentum 45
Price trend over the last 3–12 months (market factor)
52W Momentum 55
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Grand Brilliance Group Holdings Limited, an investment holding company, engages in supplying of medical devices in Hong Kong. The company offers medical consumables; medical instruments; and medical equipment, as well as develops healthcare products.

Full company description

Grand Brilliance Group Holdings Limited, an investment holding company, engages in supplying of medical devices in Hong Kong. The company offers medical consumables; medical instruments; and medical equipment, as well as develops healthcare products. It also provides medical device solutions, such as market trend analysis, sourcing of medical devices, after-sale services, technical support and training services, medical devices leasing services, and quality assurance services; and autonomous mobile robots solutions, as well as holds trademarks. The company sells its products to government department, hospitals, elderly home, universities, non-private organization, and individual end users. Grand Brilliance Group Holdings Limited was founded in 1997 and is based in Tsuen Wan, Hong Kong.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Grand Brilliance Group Holdings Ltd reported revenue of HK$101M in FY2026 versus HK$72.0M in FY2022, a compound +8.8%/yr. Reported net income was HK$8.4M in FY2026, compounding +20.1%/yr from FY2022.

Growth Quality 55/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2026)
HK$101M
Latest YoY
+6.6%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+9.5%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.5%
Avg. growth/yr (10Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.7%
Revenue +8.8%/yr
FY22 HK$72.0M
FY23 HK$76.7M
FY24 HK$81.9M
FY25 HK$94.4M
FY26 HK$101M
Net income +20.1%/yr
FY22 HK$4.0M
FY23 HK$7.6M
FY24 HK$7.9M
FY25 HK$9.5M
FY26 HK$8.4M
Character of growth · EPS growth decomposed (2016-2026) −4.2 % p.a.
Revenue per share +6.9 pp

of which total revenue +6.9 pp · buybacks/dilution +0.0 pp

EBIT margin −14.5 pp
Tax rate +1.1 pp
Residual (interest, one-offs) +2.2 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch 8372: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Grand Brilliance Group Holdings Ltd · Fair Value
HK$0.1500 +4%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Grand Brilliance Group Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8372

Peer Group

Medical Distribution · 77 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 60 · Top 25%
Fair Value upside +4% · Above median
Return on equity (TTM) 7% · Above median
Return on assets 3% · Above median
Net margin (TTM) 8% · Top 25%
Operating margin (TTM) 8% · Top 25%
Revenue growth -9% · Bottom 25%
Dividend yield (TTM) 2.3% · Below median

Valuation Multiples vs Medical Distribution median · lower = cheaper

P/E (TTM) 14.0× · Cheaper than median
P/B 0.96× · Pricier than median
P/S (TTM) 1.11× · Pricier than 75% of peers
P/FCF 12.2× · Pricier than 75% of peers
EV/EBITDA 7.8× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 39 · sector 31
FUTURE 0 · sector 17
PAST 28 · sector 22
HEALTH 0 · sector 97
DIVIDEND 45 · sector 53

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $878.73 $819.31 -7%
Cencora, Inc COR $314.17 $211.07 -33%
Cardinal Health, Inc CAH $234.16 $141.77 -39%
Henry Schein, Inc HSIC $90.74 $71.70 -21%
Shanghai Pharmaceuticals Holding 601607 ¥16.56 ¥33.96 +105%
Sinopharm Group 1099 HK$16.75 HK$58.67 +250%
Galenica AG GALE CHF 80.85 CHF 61.79 -24%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥21.49 ¥28.65 +33%
Jointown Pharmaceutical Group 600998 ¥5.04 ¥9.84 +95%
Asker Healthcare Group ASKER kr 80.00 kr 28.26 -65%

Compare Grand Brilliance Group Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Grand Brilliance Group Holdings Ltd (8372) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$0.1500 versus a price of HK$0.1440, about +4% (fairly valued).
What is the fair value of 8372?
Our model-based fair value for Grand Brilliance Group Holdings Ltd is HK$0.1500 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$0.1440.
What is the quality score of 8372?
Grand Brilliance Group Holdings Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Grand Brilliance Group Holdings Ltd (8372)?
Grand Brilliance Group Holdings Ltd reported trailing-twelve-month revenue of about HK$101M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 8372?
The net profit margin of Grand Brilliance Group Holdings Ltd is about 8.4%, meaning it keeps roughly 8.4% of revenue as net income. Based on the latest reported figures.
Does Grand Brilliance Group Holdings Ltd pay a dividend?
Grand Brilliance Group Holdings Ltd currently shows a dividend yield of about 2.27% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Grand Brilliance Group Holdings Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.